A U.S. District Court recently ruled against Zydus and Lupin, finding Astellas's patent for Myrbetriq was not invalid. Both ...

Lupin Ltd. and Zydus Lifesciences Ltd. shares fell sharply after a US court upheld Astellas Pharma's patent on Myrbetriq, ...

The litigation was initiated by Astellas Pharma against Zydus Lifesciences concerning the validity of the ‘780 patent’, which ...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

The United States District Court for the District of Delaware has passed an order against Lupin Ltd in the matter of Myrbetriq® patent case.

Astellas, a Japanese pharmaceutical company, views Vietnam as a potential market due to the country's stable economic growth ...

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs.

BEIJING—A Japanese employee of Astellas Pharma Inc. who has been detained here on suspicion of espionage since March of last year was indicted in mid-August, a source close to Japan-China ...

A federal judge in Delaware ruled in favor of Astellas Pharma Inc. on Tuesday, affirming the validity of the company's patent ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...